Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review

Xie,Xiaobao; Lin,Yan; Cao,Yang; Dong,Weimin; Wu,Wei; Zhu,Yuandong; Liu,Deliang; Li,Haiqian; Li,Qing; Gu,Weiying

doi:10.3892/ol.2018.8237

Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review

Authors:
- Xiaobao Xie
- Yan Lin
- Yang Cao
- Weimin Dong
- Wei Wu
- Yuandong Zhu
- Deliang Liu
- Haiqian Li
- Qing Li
- Weiying Gu
View Affiliations

Affiliations: Department of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China, Department of Pathology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China
Published online on: March 12, 2018 https://doi.org/10.3892/ol.2018.8237
Pages: 7207-7214

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal transplant recipients exhibit an increased risk of developing plasma cell neoplasms (PCNs; comprising multiple myeloma and plasmacytoma); however, multiple myeloma manifesting with refractory extramedullary plasmacytomas associated with Epstein‑Barr virus are markedly rare in these patients. In the present case report, an unusual case of refractory multiple myeloma with multiple extramedullary plasmacytoma (including liver, vertebrae, breast, muscle, skin and soft tissues) was presented. The patient exhibited mild bone marrow infiltration which was successfully treated with novel agents, including bortezomib and lenalidomide, followed by autologous stem cell transplantation (ASCT). In addition, the patient was a renal transplant recipient who achieved a partial clinical remission with controllable therapy‑related toxicity effects. Therefore, the present case indicated that ASCT is an effective and safe salvage therapy for renal transplant recipients with secondary extramedullary plasmacytomas and who are resistant to traditional chemotherapy (bortezomib and lenalidomide). ASCT was well‑tolerated in the renal transplant recipient.

View Figures

View References

1	Andrés A: Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol. 56:71–85. 2005. View Article : Google Scholar : PubMed/NCBI
2	Nalesnik MA: Plasma cell tumors in transplant patients. Blood. 121:1247–1249. 2013. View Article : Google Scholar : PubMed/NCBI
3	Caillard S, Dharnidharka V, Agodoa L, Bohen E and Abbott K: Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 80:1233–1243. 2005. View Article : Google Scholar : PubMed/NCBI
4	Engels EA, Clarke CA, Pfeiffer RM, Lynch CF, Weisenburger DD, Gibson TM, Landgren O and Morton LM: Plasma cell neoplasms in US solid organ transplant recipients. Am J Transplant. 13:1523–1532. 2013. View Article : Google Scholar : PubMed/NCBI
5	Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, et al: Plasmacytic post-transplant lymphoproliferative disorder: A case series of nine patients. Transpl Int. 26:616–622. 2013. View Article : Google Scholar : PubMed/NCBI
6	Joseph G, Barker RL, Yuan B, Martin A, Medeiros J and Peiper SC: Posttransplantation plasma cell dyscrasias. Cancer. 74:1959–1964. 1994. View Article : Google Scholar : PubMed/NCBI
7	Ueda K, Matsui H, Watanabe T, Seki J, Ichinohe T, Tsuji Y, Matsumura K, Sawai Y, Ida H, Ueda Y and Chiba T: Spontaneous rupture of liver plasmacytoma mimicking hepatocellular carcinoma. Intern Med. 49:653–657. 2010. View Article : Google Scholar : PubMed/NCBI
8	El Maaroufi H, Doghmi K, Rharrassi I and Mikdame M: Extramedullary plasmacytoma of the liver. Hematol Oncol Stem Cell Ther. 5:172–173. 2012. View Article : Google Scholar : PubMed/NCBI
9	Tao K, Zhu X, Xu W, Chen Z and Lu H: A clinicopathologic and immunohistochemical study of diffuse large B-cell lymphoma. Zhonghua Bing Li Xue Za Zhi. 31:112–115. 2002.PubMed/NCBI
10	Hu Y, Chen L, Sun CY, She XM, Ai LS and Qin Y: Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients. Chin Med J (Engl). 124:2981–2985. 2011.PubMed/NCBI
11	Nau KC and Lewis WD: Multiple myeloma: Diagnosis and treatment. Am Fam Physician. 78:853–859. 2008.PubMed/NCBI
12	Rahmouni A, Divine M, Mathieu D, Golli M, Dao TH, Jazaerli N, Anglade MC, Reyes F and Vasile N: Detection of multiple myeloma involving the spine: Efficacy of fat-suppression and contrast-enhanced MR imaging. AJR Am J Roentgenol. 160:1049–1052. 1993. View Article : Google Scholar : PubMed/NCBI
13	Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever. Zhonghua Xue Ye Xue Za Zhi. 33:693–696. 2012.(In Chinese). PubMed/NCBI
14	Choi JH, Park BB, Suh C, Won JH, Lee WS and Shin HJ: Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders. J Korean Med Sci. 25:523–526. 2010. View Article : Google Scholar : PubMed/NCBI
15	Opelz G and Döhler B: Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant. 4:222–230. 2004. View Article : Google Scholar : PubMed/NCBI
16	Salama S, Todd S, Cina DP and Margetts P: Cutaneous presentation of post-renal transplant lymphoproliferative disorder: A series of four cases. J Cutan Pathol. 37:641–653. 2010. View Article : Google Scholar : PubMed/NCBI
17	Nalesnik MA: Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res. 159:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
18	Richendollar BG, Hsi ED and Cook JR: Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: Clinical and pathologic features. Am J Clin Pathol. 132:581–588. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kuppachi S, Naina HV, Self S and Fenning R: Plasmacytoma-like post-transplantation lymphoproliferative disorder confined to the renal allograft: A case report. Transplant Proc. 45:2791–2794. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kamdar KY, Rooney CM and Heslop HE: Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 16:274–280. 2011. View Article : Google Scholar : PubMed/NCBI
21	Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, Lehmkuhl H, Gärtner B, Anagnostopoulos I and Riess H: Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: A prospective analysis of 8 cases. Haematologica. 96:1067–1071. 2011. View Article : Google Scholar : PubMed/NCBI
22	McFarlane R, Hurst S, Sabath D, George E and Argenyi Z: A rare case of plasmacytoma-like post-transplant lymphoproliferative disorder presenting in the skin of a lung transplant patient. J Cutan Pathol. 35:599–602. 2008. View Article : Google Scholar : PubMed/NCBI
23	Bidros M, Bauer F, Codreanu I and Dasanu CA: High-grade solitary extramedullary plasmacytoma arising in skeletal muscle of a kidney transplant recipient. Leuk Res. 35:e181–e183. 2011. View Article : Google Scholar : PubMed/NCBI
24	Galieni P, Cavo M, Avvisati G, Pulsoni A, Falbo R, Bonelli MA, Russo D, Petrucci MT, Bucalossi A and Tura S: Solitary plasmacytoma of bone and extramedullary plasmacytoma: Two different entities? Ann Oncol. 6:687–691. 1995. View Article : Google Scholar : PubMed/NCBI
25	Petrucci MT, Tirindelli MC, De Muro M, Martini V, Levi A and Mandelli F: Extramedullary liver plasmacytoma a rare presentation. Leuk Lymphoma. 44:1075–1076. 2003. View Article : Google Scholar : PubMed/NCBI
26	Plant AS, Venick RS, Farmer DG, Upadhyay S, Said J and Kempert P: Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients. Pediatr Blood Cancer. 60:E137–E139. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hanto DW: Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 46:381–394. 1995. View Article : Google Scholar : PubMed/NCBI
28	Renoult E, Bertrand F and Kessler M: Monoclonal gammopathies in HBsAg-positive patients with renal transplants. N Engl J Med. 318:12051988. View Article : Google Scholar : PubMed/NCBI
29	Holmes RD and Sokol RJ: Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant. 6:456–464. 2002. View Article : Google Scholar : PubMed/NCBI
30	Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS and Blayney DW: Lymphoma after solid organ transplantation: Risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 27:3354–3362. 2009. View Article : Google Scholar : PubMed/NCBI
31	Taylor AL, Marcus R and Bradley JA: Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 56:155–167. 2005. View Article : Google Scholar : PubMed/NCBI
32	Samolitis NJ, Bharadwaj JS, Weis JR and Harris RM: Post-transplant lymphoproliferative disorder limited to the skin. J Cutan Pathol. 31:453–457. 2004. View Article : Google Scholar : PubMed/NCBI
33	Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL and Fonseca R: Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 119:4391–4394. 2012. View Article : Google Scholar : PubMed/NCBI
34	Rajkumar SV and Kumar S: Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc. 91:101–119. 2016. View Article : Google Scholar : PubMed/NCBI
35	Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, et al: Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol. 167:563–565. 2014. View Article : Google Scholar : PubMed/NCBI
36	Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A and Avigdor A: Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD)-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis. Br J Haematol. 166:702–710. 2014. View Article : Google Scholar : PubMed/NCBI
37	Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, et al: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia. 23:1337–1341. 2009. View Article : Google Scholar : PubMed/NCBI
38	Saboo SS, Fennessy F, Benajiba L, Laubach J, Anderson KC and Richardson PG: Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. J Clin Oncol. 30:e175–e179. 2012. View Article : Google Scholar : PubMed/NCBI
39	Calvo-Villas JM, Alegre A, Calle C, Hernández MT, Garcia-Sánchez R and Ramirez G: GEM-PETHEMA/Spanish MyelomaGroup, Spain: Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol. 87:281–284. 2011. View Article : Google Scholar : PubMed/NCBI